SEC Tracker
Get the app

Pluri PLUR

Pluri Q3 FY26: revenue $167K, down 61%; diluted EPS −$0.55

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Pluri reported for Q3 FY26, the quarter ended Mar 31, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$167K−61% from $427K in Q3 FY2510-Q income statement, on EDGAR
  2. Net income−$5.5MAgainst −$6.1M in Q3 FY2510-Q income statement, on EDGAR
  3. Diluted EPS−$0.55Against −$0.94 in Q3 FY2510-Q income statement, on EDGAR
  4. Cash and cash equivalents$3.4M−60% from $8.5M in Q3 FY2510-Q balance sheet, on EDGAR
  5. Cash from operations−$4.5MAgainst −$4.3M in Q3 FY2510-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Pluri files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. ProPhase Labs PRPH public float $15M, Jun 30, 2025
  2. Akari Therapeutics AKTX public float $15M, Jun 30, 2025
  3. X4 Pharmaceuticals XFOR public float $15M, Jun 30, 2025
  4. CalciMedica CALC public float $16M, Jun 30, 2025
  5. Lipocine LPCN public float $16M, Jun 30, 2025